Recent advancements highlighted by organizations like ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) focus on optimizing pharmacokinetic profiles in joint arthroplasty to prevent deep periprosthetic joint infections. The technique is known as Intraosseous Regional Administration (IORA). Instead of relying on traditional, passive systemic intravenous delivery—which often fails to achieve high enough tissue concentrations in the surgical field without causing systemic toxicity—IORA decouples local tissue concentration from systemic exposure. Technique and Device Details During surgery, after inflating a tourniquet to isolate the operative limb, prophylactic antibiotics (such as vancomycin) are injected directly into the venous sinusoids of the metaphyseal bone (typically the proximal medial tibia). The specialized equipment utilized for this access is broadly referred to as an Intraosseous Vascular Access System or Intraosseous (IO) Needle System. Widely utilized commercial options include powered drivers and disposable needles such as the EZ-IO system (Teleflex) or manual intraosseous needles (such as those by Cook Medical). Key Clinical Benefits - High Local Concentration: Achieves tissue antibiotic levels 5 to 15 times higher than intravenous administration. - Maximal Safety: Minimizes systemic peak levels, avoiding adverse side effects like renal toxicity or rapid infusion reactions. - Workflow Efficiency: The rapid infusion takes only 1 to 2 minutes right before the surgical incision, aligning perfectly with preoperative timing guidelines.

Imagine giving your patients powerful postoperative relief without the haunting shadow of opioid dependency. Introducing suzetrigine (Journavx™)—the FDA-approved, first-in-class NaV1.8 selective sodium channel blocker. By stopping pain signals at the peripheral source, it completely bypasses central nervous system side effects like sedation. Recent clinical breakthroughs are redefining recovery limits: an astonishing 89% of total joint replacement patients achieved a completely opioid-free recovery, while 90.9% of plastic surgery patients bypassed opioid rescue entirely. This is a clinical paradigm shift that protects your patients and elevates your practice standards. Don´t miss on this new research that may help with your clinical practice. Join our discussion, share your insights, and lead the non-opioid recovery revolution! Official Research Non Opiod pain Treatment in joint replacement and Orthopaedic Surgery

We are pleased to share the August 2026 WAIOT Newsletter, featuring the latest international activities, scientific updates, and opportunities for our members. 📌 In this edition: 🇲🇾 WAIOT at the 7th ASAMI-BR & ILLRS World Congress 2026 (Malaysia) 🇪🇬 WAIOT participation in the EOA Infection Symposium during the 78th Annual International Orthopaedic Conference 🔬 Research Spotlight: our latest publication on DTT-assisted urine culture pre-treatment, published in Microbiology Spectrum 📝 Last Call for submissions to the Antibiotics Special Issue "Single-Stage Management of Musculo-Skeletal Infections" (Impact Factor 5.5, Double Q1, with a special discount for WAIOT Members) 🎉 Plus an exclusive preview of the WAIOT World Congress 2027, celebrating the 10th Anniversary of WAIOT in Buenos Aires, Argentina. 📖 Read the newsletter here: 👉 https://waiot.world/so/44PzQlsfC?languageTag=en&cid=00590adf-b2f9-4d38-a2b4-e3b46fd814f9&region=c09c25db-bda9-4d5b-aa86-9bd7460d1300 💬 We'd love to hear from you! - Which article or activity caught your attention the most? - Are you planning to attend any of the upcoming congresses? - Do you have a recent publication or WAIOT activity that you'd like to feature in a future newsletter? Let's continue growing our international WAIOT community through collaboration, research, and knowledge sharing.